SKVI.US Skinvisible Inc
- Market cap
- USD 973K
- P/E
- -
- P/B
- 133.65x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is SKVI.US undervalued?
Graham numberThe Graham number of Skinvisible Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Skinvisible Inc fundamental analysis
No fundamental analysis for Skinvisible Inc yet.
Skinvisible Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Skinvisible Inc
Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its flagship product, Invisicare, is a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. The company also offers non-dermatological formulations…
Full company profileSkinvisible Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Skinvisible Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 109K | 629K | 69.3K | 43.2K | 153K | 663K | 279K | 20.0K | 20.0K | 20.0K | 20.0K |
| Gross Profit | 71.8K | 587K | 48.6K | 25.6K | 276K | 660K | 274K | 20.0K | 20.0K | 20.0K | 20.0K |
| Operating Income | -842K | -364K | -598K | -540K | -254K | 188K | -238K | -490K | -590K | -496K | -504K |
| EBITDA | - | -217K | 1.21M | -658K | -222K | 158K | -43.3K | -477K | 124K | -472K | -484K |
| Net Income | -2.05M | -1.83M | 158K | -1.70M | -1.45M | -1.07M | -1.22M | -2.38M | -566K | -1.06M | -1.07M |
| EPS | - | -0.67 | 0.05 | -0.38 | -0.32 | -0.24 | -0.27 | -0.52 | -0.11 | -0.20 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 340K | 632K | 220K | 182K | 200K | 227K | 247K | 163K | 158K | 128K | 119K |
| Total Liabilities | 6.45M | 7.39M | 4.94M | 3.19M | 4.66M | 5.64M | 6.89M | 9.19M | 9.38M | 10.4M | 10.6M |
| Shareholders' Equity | -6.11M | -6.76M | -4.72M | -3.01M | -4.45M | -5.42M | -6.64M | -9.02M | -9.22M | -10.3M | -10.5M |
| Cash & Short-term Investments | 3.02K | 23.3K | 2.48K | 1.30K | 35.9K | 66.0K | 81.4K | 888.00 | 10.3K | 2.62K | 1.80K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -244K | -13.9K | -34.3K | -1.59M | 45.8K | 375K | 45.2K | -77.2K | -69.8K | -38.4K | -3.29K |
| Capital Expenditure | 15.0K | 15.0K | 11.5K | 26.1K | 16.8K | 2.53K | 2.53K | 9.33K | 9.22K | 4.09K | 0.00 |
| Free Cash Flow | - | -28.9K | -45.8K | -154K | 29.0K | 354K | 42.6K | -86.5K | -79.1K | -42.5K | -3.29K |
| Ratios | |||||||||||
| ROA | -603.9% | -289.0% | 71.8% | -936.5% | -722.9% | -472.0% | -496.3% | -1,462.8% | -357.5% | -834.1% | -894.9% |
| Net Profit Margin | -1,883.4% | -290.4% | 228.3% | -3,943.2% | -948.4% | -161.7% | -438.6% | -11,912.2% | -2,828.3% | -5,320.2% | -5,343.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Skinvisible Inc dividends
Skinvisible Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Jan 4, 2019.
Who owns Skinvisible Inc
- Insiders 3.53%
- Institutions 0.00%
- Public & others 96.48%
- Shares outstanding 5.40M
- Free float 5.25M
Skinvisible Inc company profile
- Company name
- Skinvisible Inc
- Ticker
- SKVI.US
- Exchange
- USA Stocks
- Listed since
- Jan 7, 1999
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 2
- Fiscal year end
- December
- Address
- 6320 South Sandhill Road, Las Vegas, NV, United States, 89120
- Phone
- 702 433 7154
- Website
- skinvisible.com
About Skinvisible Inc
Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its flagship product, Invisicare, is a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. The company also offers non-dermatological formulations for women's health, pain management, and other markets. In addition, it engages in the development and licensing of topical prescription and over-the-counter products, as well as the co-development of formulations for pharmaceutical clients. Further, the company provides solutions to pharmaceutical companies by reformulating products coming off patent with a new Invisicare patent, and new product benefits and line extensions. It has a licensing and collaboration agreement with Ovation Science for the use of Invisicare technology with cannabinoids for topical/transdermal products, including new formulations with THC-V targeting obesity and metabolic health. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.
Skinvisible Inc management
2- Mr. Terry H. HowlettPresident, CEO, CFO & Director · born 1948
- Dr. James A. Roszell Ph.D.Head of Research & Development